A detailed history of Israel Englander (Millennium Management LLC) transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 204,598 shares of CRVS stock, worth $1.76 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
204,598
Previous 23,281 778.82%
Holding current value
$1.76 Million
Previous $41,000 807.32%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.36 - $2.29 $246,591 - $415,215
181,317 Added 778.82%
204,598 $372,000
Q1 2024

May 15, 2024

SELL
$1.76 - $2.41 $30,895 - $42,305
-17,554 Reduced 42.99%
23,281 $41,000
Q4 2023

Feb 14, 2024

BUY
$1.08 - $1.92 $44,101 - $78,403
40,835 New
40,835 $71,000
Q1 2023

May 15, 2023

BUY
$0.65 - $0.92 $84,439 - $119,514
129,907 Added 6.84%
2,029,423 $1.85 Million
Q4 2022

Feb 14, 2023

SELL
$0.74 - $1.04 $270,689 - $380,427
-365,796 Reduced 16.15%
1,899,516 $1.62 Million
Q3 2022

Nov 14, 2022

SELL
$0.71 - $1.17 $300,068 - $494,478
-422,631 Reduced 15.72%
2,265,312 $1.85 Million
Q2 2022

Aug 15, 2022

SELL
$0.87 - $2.03 $30,968 - $72,259
-35,596 Reduced 1.31%
2,687,943 $2.66 Million
Q1 2022

May 16, 2022

SELL
$1.46 - $2.48 $286,919 - $487,369
-196,520 Reduced 6.73%
2,723,539 $4.47 Million
Q4 2021

Feb 14, 2022

BUY
$2.34 - $5.31 $5.46 Million - $12.4 Million
2,331,787 Added 396.38%
2,920,059 $7.04 Million
Q3 2021

Nov 15, 2021

BUY
$1.89 - $8.53 $863,421 - $3.9 Million
456,837 Added 347.58%
588,272 $2.85 Million
Q2 2021

Aug 16, 2021

BUY
$2.46 - $3.14 $79,553 - $101,544
32,339 Added 32.63%
131,435 $351,000
Q1 2021

May 17, 2021

SELL
$2.86 - $4.77 $64,412 - $107,429
-22,522 Reduced 18.52%
99,096 $305,000
Q4 2020

Feb 16, 2021

SELL
$3.56 - $4.86 $923,909 - $1.26 Million
-259,525 Reduced 68.09%
121,618 $433,000
Q3 2020

Nov 16, 2020

SELL
$2.6 - $5.37 $2.11 Million - $4.36 Million
-811,599 Reduced 68.04%
381,143 $1.53 Million
Q2 2020

Aug 14, 2020

BUY
$2.01 - $4.05 $323,575 - $651,981
160,983 Added 15.6%
1,192,742 $3.24 Million
Q1 2020

May 14, 2020

BUY
$1.74 - $5.98 $403,556 - $1.39 Million
231,929 Added 29.0%
1,031,759 $2.18 Million
Q4 2019

Feb 14, 2020

SELL
$2.56 - $5.44 $390,059 - $828,876
-152,367 Reduced 16.0%
799,830 $4.35 Million
Q3 2019

Nov 14, 2019

BUY
$3.01 - $6.5 $2.64 Million - $5.7 Million
877,462 Added 1174.1%
952,197 $2.87 Million
Q2 2019

Aug 14, 2019

BUY
$3.3 - $4.58 $184,486 - $256,044
55,905 Added 296.89%
74,735 $280,000
Q1 2019

May 14, 2019

SELL
$3.75 - $4.97 $155,317 - $205,847
-41,418 Reduced 68.75%
18,830 $76,000
Q4 2018

Feb 14, 2019

BUY
$3.29 - $8.94 $75,268 - $204,529
22,878 Added 61.22%
60,248 $221,000
Q3 2018

Nov 14, 2018

SELL
$8.58 - $11.4 $2.64 Million - $3.51 Million
-308,204 Reduced 89.19%
37,370 $321,000
Q2 2018

Aug 14, 2018

SELL
$9.42 - $13.73 $2.45 Million - $3.57 Million
-259,729 Reduced 42.91%
345,574 $3.79 Million
Q1 2018

May 15, 2018

BUY
$7.48 - $11.53 $4.09 Million - $6.3 Million
546,286 Added 925.64%
605,303 $6.98 Million
Q4 2017

Feb 14, 2018

BUY
$9.3 - $16.93 $353,381 - $643,306
37,998 Added 180.78%
59,017 $611,000
Q3 2017

Nov 14, 2017

BUY
$11.3 - $17.23 $237,514 - $362,157
21,019
21,019 $335,000

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $401M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.